A new molecular paradigm in mycosis fungoides and Sézary syndrome

Seminars in Diagnostic Pathology

Volumn 34, Issue 1, 2017, Pages 15-21

  Elenitoba Johnson, Kojo S J ^a   Wilcox, Ryan ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Molecular; Mycosis fungoides; Whole genome sequencing

Indexed keywords

BROMODOMAIN INHIBITOR; CALCINEURIN INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; IPILIMUMAB; JANUS KINASE INHIBITOR; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOGAMULIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; RUXOLITINIB; T LYMPHOCYTE RECEPTOR; TOFACITINIB;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOTHRIPSIS; COPY NUMBER VARIATION; DRUG SENSITIVITY; EPIGENETICS; GENE MUTATION; GENOME ANALYSIS; HUMAN; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; ULTRAVIOLET RADIATION; GENETICS; SKIN TUMOR;

HUMANS; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 85009259815     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2016.11.002     Document Type: Article

References (75)

1. 1 Watanabe, R., Gehad, A., Yang, C., et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med, 7(279), 2015, 279ra39.
2. 2 Clark, R.A., Watanabe, R., Teague, J.E., et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med, 4(117), 2012, 117ra7.
3. 3 Kiel, M.J., Sahasrabuddhe, A.A., Rolland, D.C., et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun, 6, 2015, 8470.
4. 4 Choi, J., Goh, G., Walradt, T., et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 47:9 (2015), 1011–1019.
5. 5 da Silva Almeida, A.C., Abate, F., Khiabanian, H., et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 47:12 (2015), 1465–1470.
6. 6 Wang, L., Ni, X., Covington, K.R., et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47:12 (2015), 1426–1434.
7. 7 Ungewickell, A., Bhaduri, A., Rios, E., et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47:9 (2015), 1056–1060.
8. 8 Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
9. 9 Morales Suarez-Varela, M.M., Llopis Gonzalez, A., Marquina Vila, A., Bell, J., Mycosis fungoides: review of epidemiological observations. Dermatology 201:1 (2000), 21–28.
10. 10 Wilcox, R.A., Cutaneous T-cell lymphoma. 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:11 (2011), 928–948.
11. 11 Marculescu, R., Le, T., Simon, P., Jaeger, U., Nadel, B., V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites. J Exp Med 195:1 (2002), 85–98.
12. 12 Lewis, S.M., Agard, E., Suh, S., Czyzyk, L., Cryptic signals and the fidelity of V(D)J joining. Mol Cell Biol 17:6 (1997), 3125–3136.
13. 13 Gostissa, M., Alt, F.W., Chiarle, R., Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol 29 (2011), 319–350.
14. 14 Mendes, R.D., Sarmento, L.M., Cante-Barrett, K., et al. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood 124:4 (2014), 567–578.
15. 15 Papaemmanuil, E., Rapado, I., Li, Y., et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 46:2 (2014), 116–125.
16. 16 Teng, G., Maman, Y., Resch, W., et al. RAG represents a widespread threat to the lymphocyte genome. Cell 162:4 (2015), 751–765.
17. 17 Stephens, P.J., Greenman, C.D., Fu, B., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:1 (2011), 27–40.
18. 18 Kadoch, C., Hargreaves, D.C., Hodges, C., et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45:6 (2013), 592–601.
19. 19 Blais, A., Dynlacht, B.D., E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 19:6 (2007), 658–662.
20. 20 Baylin, S.B., Jones, P.A., A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer 11:10 (2011), 726–734.
21. 21 Berger, S.L., The complex language of chromatin regulation during transcription. Nature 447:7143 (2007), 407–412.
22. 22 Kouzarides, T., Chromatin modifications and their function. Cell. 128:4 (2007), 693–705.
23. 23 Romo-Tena, J., Gomez-Martin, D., Alcocer-Varela, J., CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 12:12 (2013), 1171–1176.
24. 24 Linsley, P.S., Greene, J.L., Tan, P., et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:6 (1992), 1595–1604.
25. 25 Sekulic, A., Liang, W.S., Tembe, W., et al. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:cd28 fusion. Mol Genet Genom Med 3:2 (2015), 130–136.
26. 26 Vaque, J.P., Gomez-Lopez, G., Monsalvez, V., et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123:13 (2014), 2034–2043.
27. 27 Riley, J.L., PD-1 signaling in primary T cells. Immunol Rev 229:1 (2009), 114–125.
28. 28 Mishra, A., et al., La Perle, K., Kwiatkowski, S., Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov 6:9 (2016), 986–1005.
29. 29 Hidaka, T., Nakahata, S., Hatakeyama, K., et al. Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood 112:2 (2008), 383–393.
30. 30 Zheng, W., Flavell, R.A., The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:4 (1997), 587–596.
31. 31 Thome, M., Tschopp, J., TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1. Trends Immunol 24:8 (2003), 419–424.
32. 32 Lenz, G., Davis, R.E., Ngo, V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:5870 (2008), 1676–1679.
33. 33 Zhang, J., Chang, C.C., Lombardi, L., Dalla-Favera, R., Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9:7 (1994), 1931–1937.
34. 34 Legarda-Addison, D., Ting, A.T., Negative regulation of TCR signaling by NF-kappaB2/p100. J Immunol 178:12 (2007), 7767–7778.
35. 35 McGirt, L.Y., Jia, P., Baerenwald, D.A., et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 126:4 (2015), 508–519.
36. 36 Kiel, M.J., Velusamy, T., Rolland, D., et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124:9 (2014), 1460–1472.
37. 37 Koskela, H.L., Eldfors, S., Ellonen, P., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366:20 (2012), 1905–1913.
38. 38 Scott, L.J., Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs 73:8 (2013), 857–874.
39. 39 McKeage, K., Ruxolitinib: a review in polycythaemia vera. Drugs 75:15 (2015), 1773–1781.
40. 40 Wilcox, R.A., Wada, D.A., Ziesmer, S.C., et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:14 (2009), 2936–2944.
41. 41 Berger, C.L., Hanlon, D., Kanada, D., et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99:8 (2002), 2929–2939.
42. 42 Wilcox, R.A., A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol 91:1 (2016), 113–122.
43. 43 Vonderheid, E.C., Boselli, C.M., Conroy, M., et al. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 124:3 (2005), 651–661.
44. 44 McCusker, M.E., Garifallou, M., Bogen, S.A., Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 158:10 (1997), 4984–4991.
45. 45 Rohr, J., Guo, S., Hu, D., et al. CD28 mutations in peripheral T-cell lymphomagenesis and progression. Blood Annu Meet Abstr, 124(21), 2014, 1681.
46. 46 Yoo, H.Y., Sung, M.K., Lee, S.H., et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46:4 (2014), 371–375.
47. 47 Sekulic, A., Liang, W.S., Tembe, W., et al. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:cd28 fusion. Mol Genet Genom Med 3:2 (2015), 130–136.
48. 48 Zhang, Q., Wang, H.Y., Wei, F., et al. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 192:6 (2014), 2913–2919.
49. 49 Suga, H., Sugaya, M., Miyagaki, T., et al. The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134:5 (2014), 1428–1435.
50. 50 van der Fits, L., Out-Luiting, J.J., van Leeuwen, M.A., et al. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome. J Invest Dermatol 132:2 (2012), 440–447.
51. 51 Nakagawa, M., Schmitz, R., Xiao, W., et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 211:13 (2014), 2497–2505.
52. 52 Williams, T.M., Moolten, D., Burlein, J., et al. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science. 254:5039 (1991), 1791–1794.
53. 53 Geskin, L.J., Viragova, S., Stolz, D.B., Fuschiotti, P., Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 125:18 (2015), 2798–2805.
54. 54 Wang, T., Feldman, A.L., Wada, D.A., et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 123:19 (2014), 3007–3015.
55. 55 Vieyra-Garcia, P.A., Wei, T., Naym, D.G., et al. STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clinical cancer research: an official journal of the American Association for. Cancer Res 22:13 (2016), 3328–3339.
56. 56 Nakatsukasa, H., Zhang, D., Maruyama, T., et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells. Nat Immunol 16:10 (2015), 1077–1084.
57. 57 Jenkins, S.J., Ruckerl, D., Cook, P.C., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332:6035 (2011), 1284–1288.
58. 58 Bradford, P.T., Devesa, S.S., Anderson, W.F., Toro, J.R., Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 113:21 (2009), 5064–5073.
59. 59 Talpur, R., et al., Singh, L., Daulat, S., Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clinical Cancer Res 18:18 (2012), 5051–5060.
60. 60 Hughes, C.F., Khot, A., McCormack, C., et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 125:1 (2015), 71–81.
61. 61 Agar, N.S., Wedgeworth, E., Crichton, S., et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:31 (2010), 4730–4739.
62. 62 Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
63. 63 Dubovsky, J.A., Beckwith, K.A., Natarajan, G., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:15 (2013), 2539–2549.
64. 64 Wilcox, R.A., Sun, D.X., Novak, A., Dogan, A., Ansell, S.M., Feldman, A.L., Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia 24:1 (2010), 229–232.
65. 65 Woollard, W.J., Pullabhatla, V., Lorenc, A., et al. Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome. Blood 127:26 (2016), 3387–3397.
66. 66 Witzig, T.E., Reeder, C., Han, J.J., et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126:3 (2015), 328–335.
67. 67 Kamstrup, M.R., Gjerdrum, L.M., Biskup, E., et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 116:14 (2010), 2504–2512.
68. 68 Duvic, M., Pinter-Brown, L.C., Foss, F.M., et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125:12 (2015), 1883–1889.
69. 69 Wilcox, R.A., Mogamulizumab: 2 birds, 1 stone. Blood 125:12 (2015), 1847–1848.
70. 70 Yang, Y., Shaffer, A.L., 3rd, Emre, N.C., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:6 (2012), 723–737.
71. 71 Boonk, S.E., Zoutman, W.H., Marie-Cardine, A., et al. Evaluation of immunophenotypic and molecular biomarkers for sezary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol 136:7 (2016), 1364–1372.
72. 72 Clark, A.S., Karasic, T.B., DeMichele, A., et al. Palbociclib (PD0332991) – a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development. JAMA Oncol 2:2 (2016), 253–260.
73. 73 Jones, J.A., Rupert, A.S., Poi, M., et al. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol 89:1 (2014), 19–24.
74. 74 Prasad, A., Rabionet, R., Espinet, B., et al. Identification of Gene Mutations and Fusion Genes in Patients with Sezary Syndrome. J Invest Dermatol 136:7 (2016), 1490–1499.
75. 75 Saddler, C., Ouillette, P., Kujawski, L., et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:3 (2008), 1584–1593.